

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
Wii Study	Managing Fatigue Using Virtual Reality for Post-Operative Lung Cancer Patients: Understanding the Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Patient's Symptom Experience	Treatment	<b>SHORE:</b> Drs. Geoffrey Lam and Charles Wilekes	Cardiovascular Research Department (616) 391-3886
2019-278 SEER-Lung	A Prospective Blood Sample Collection Study to Develop and Validate a Panel of Protein-based Biomarkers in Patients with Pulmonary Nodules	Other	<b>SHORE:</b> Dr. Glenn VanOtteren	Tara Jager (616) 391-5038 tara.jager@spectrumhealth.org
S1900E	A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A151216	Non-Squamous, Large IB, II or IIIA, any EGFR/ALK, Resected. Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial ( <u>ALCHEMIST</u> )	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
E4512	Must be enrolled in A151216. NSCLC; ALK+; Surgically Resected Early Stage. <u>Crizotinib/Placebo</u>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A081105	Must be enrolled in A151216. NSCLC; EGFR Mutant, Resected Tumor. Treatment <u>Erlotinib/Placebo</u>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A221504	A Randomized, Double-blind, Placebo-controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-small Cell Lung Cancer (Adenocarcinoma)	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

NRG LU005	<b>Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation vs Chemoradiation + Atezolizumab</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1827	<b>S1827 – MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1900B	<b>S1900B - A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA5163: INSIGNA	<b>A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1800A	<b>A Phase II RANDOMIZED Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1900A	<b>A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious Brca1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-Map Sub-Study)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

<b>SWOG LungMAP</b>	<b>A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)</b>	Screening	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>EA5162</b>	<b>Phase II study of AZD9291 (Osimertinib) advanced NSCLC Patients with Exon 20 Insertion</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>NRG LU002</b>	<b>A Randomized Phase II/III Trial for Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>NRG CC003</b>	<b>Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>S1900C</b>	<b>A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub Study)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>S1929</b>	<b>Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

CARMEN	Randomized, Open Label Phase 3 Study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous non-small Cell Lung Cancer patients with CEACAM5 positive tumors	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
MS201923_0050 (DDRiver)	A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
ADRIATIC	AstraZeneca (ADRIATIC): A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with State I-III Limited Disease Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
IPSEN MM-398- 01-03-04	RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) versus Topotecan in Patients with Small Cell Lung Cancer or after Platinum-based First-line Therapy	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
Helsinn (ANAM)	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>

---

<b>CodeBreak200: 20190009</b>	<b>A Phase III Multicenter, Randomized, Open-label, Active-controlled, Study of AMG 510 vs Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C</b>	Treatment	<b>CHCWM</b> Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
	<b>An Open Label, Single Arm, Phase IB/II Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-small Cell Lung Cancer (NSCLC) Adenocarcinoma</b>	Treatment	<b>START Midwest</b> Investigators	START Midwest (616) 954-5554

---